FILINGS
| AZN 0000901832 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2022-05-09 | 6-K | APPOINTMENT OF JOINT CORPORATE BROKERS | View Document |
| 2022-05-06 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-05-05 | 6-K | ENHERTU APPROVED IN US FOR 2L HER2+ BREAST CANCER | View Document |
| 2022-05-05 | 6-K | FARXIGA HFPEF PHASE III TRIAL MET PRIMARY ENDPOINT | View Document |
| 2022-05-05 | 6-K | ULTOMIRIS NMOSD PH. III TRIAL MET PRIMARY ENDPOINT | View Document |
| 2022-05-04 | 6-K | IMFINZI COMBO GRANTED PRIORITY REVIEW FOR BTC | View Document |
| 2022-05-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-04-29 | 6-K | RESULT OF AGM | View Document |
| 2022-04-29 | 6-K | ASTRAZENECA PLANS NEW R&D CENTRE IN MASSACHUSETTS | View Document |
| 2022-04-29 | 6-K | FIRST QUARTER 2022 RESULTS | View Document |
| 2022-04-28 | 6-K | ULTOMIRIS APPROVED IN THE US FOR ADULTS WITH GMG | View Document |
| 2022-04-27 | 6-K | ENHERTU GRANTED BTD FOR HER2-LOW BREAST CANCER | View Document |
| 2022-04-25 | 6-K | TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBO | View Document |
| 2022-04-19 | 6-K | ENHERTU GRANTED PRIORITY REVIEW FOR HER2M NSCLC | View Document |
| 2022-04-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-03-29 | 6-K | ONDEXXYA APPROVED IN JAPAN FOR FXAI REVERSAL | View Document |
| 2022-03-28 | 6-K | EVUSHELD APPROVED IN THE EU FOR COVID-19 | View Document |
| 2022-03-25 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-24 | 6-K | EVUSHELD POSITIVE EU CHMP OPINION | View Document |
| 2022-03-24 | 6-K | UPDATE ON CALLA PHASE III TRIAL OF CONCURRENT USE OF IMFINZI AND CHEMORADIOTHERA | View Document |
| 2022-03-23 | 6-K | NOTICE OF AGM | View Document |
| 2022-03-23 | 6-K | FORM 6-K | View Document |
| 2022-03-17 | 6-K | SETTLEMENT OF PATENT LITIGATION FOR ULTOMIRIS | View Document |
| 2022-03-14 | 6-K | LYNPARZA APPROVED IN US FOR EARLY BREAST CANCER | View Document |
| 2022-03-14 | 6-K | UPDATE ON US REVIEW OF FASENRA IN NASAL POLYPS | View Document |
| 2022-03-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-07 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-03-01 | 6-K | ASTRAZENECA AND NEURIMMUNE CLOSE DEAL FOR NI006 | View Document |
| 2022-02-23 | 6-K | FILING OF FORM 20-F WITH SEC | View Document |
| 2022-02-22 | IRANNOTICE | IRANNOTICE | View Document |
| 2022-02-22 | 20-F | FORM 20F | View Document |
| 2022-02-22 | 6-K | CHAIR SUCCESSION PLANNING UPDATE AND ANNUAL REPORT | View Document |
| 2022-02-22 | 6-K | ENHERTU IMPROVES PFS AND OS IN HER2-LOW BC | View Document |
| 2022-02-16 | 6-K | SAPHNELO APPROVED IN EU FOR SLE | View Document |
| 2022-02-15 | 6-K | LYNPARZA COMBO DELAYS PROGRESSION RISK IN PROSTATE | View Document |
| 2022-02-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-10 | 6-K | AZN: FULL YEAR AND Q4 2021 RESULTS | View Document |
| 2022-02-07 | SC 13G/A | View Document | |
| 2022-02-04 | SC 13G/A | SEC SCHEDULE 13G | View Document |
| 2022-02-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-01-19 | 6-K | IMFINZI IMPROVES SURVIVAL IN BILIARY TRACT CANCER | View Document |
| 2022-01-19 | 6-K | IMFINZI COMBO SHOWS UNPRECEDENTED SURVIVAL IN HCC | View Document |
| 2022-01-18 | 6-K | ENHERTU GRANTED PRIORITY REVIEW FOR BREAST CANCER | View Document |
| 2022-01-07 | 6-K | ASTRAZENECA AND NEURIMMUNE SIGN DEAL FOR NI006 | View Document |
| 2022-01-05 | 6-K | TRANSFER OF RIGHTS TO EKLIRA, DUAKLIR COMPLETED | View Document |
| 2022-01-04 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2021-12-29 | 6-K | ASTRAZENECA AND IONIS CLOSE EPLONTERSEN DEAL | View Document |
| 2021-12-21 | 6-K | ULTOMIRIS ACCEPTED FOR FDA PRIORITY REVIEW FOR GMG | View Document |
| 2021-12-20 | 6-K | TEZSPIRE APPROVED IN THE US FOR SEVERE ASTHMA | View Document |
| 2021-12-20 | 6-K | SAPHNELO RECOMMENDED FOR EU APPROVAL FOR SLE | View Document |
| 2021-12-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-12-09 | 6-K | EVUSHELD US FDA EUA | View Document |
| 2021-12-07 | 6-K | ASTRAZENECA, IONIS TO COLLABORATE ON EPLONTERSEN | View Document |
| 2021-12-01 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2021-12-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2021-11-30 | 6-K | LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIA | View Document |
| 2021-11-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-11-12 | 6-K | AZN: YEAR TO DATE AND Q3 2021 RESULTS | View Document |
| 2021-11-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2021-11-01 | 6-K | ASTRAZENECA TO TRANSFER RIGHTS TO EKLIRA, DUAKLIR | View Document |
| 2021-10-25 | 6-K | IMFINZI IMPROVED SURVIVAL IN BILIARY TRACT CANCER | View Document |
| 2021-10-18 | 6-K | AZ RECOMMENDS ADS HOLDERS REJECT MINI-TENDER OFFER | View Document |
| 2021-10-15 | 6-K | IMFINZI & TREMELIMUMAB IMPROVED OS IN LIVER CANCER | View Document |
| 2021-10-12 | 6-K | AZD7442 PHIII TRIAL POSITIVE IN COVID OUTPATIENTS | View Document |
| 2021-10-04 | 6-K | ENHERTU GRANTED BTD FOR BREAST CANCER | View Document |
| 2021-10-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2021-09-30 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-09-29 | 6-K | ASTRAZENECA TO FULLY ACQUIRE CAELUM BIOSCIENCES | View Document |
| 2021-09-28 | 6-K | SAPHNELO APPROVED IN JAPAN FOR SLE | View Document |
| 2021-09-24 | 6-K | LYNPARZA PROPEL TRIAL MEETS PRIMARY ENDPOINT | View Document |
| 2021-09-23 | 6-K | BOARD COMMITTEE CHANGE | View Document |
| 2021-09-23 | 6-K | NEW SUSTAINABILITY COMMITTEE OF THE BOARD | View Document |
| 2021-09-21 | 6-K | ASTRAZENECA $360M IRISH MANUFACTURING INVESTMENT | View Document |
| 2021-09-20 | 6-K | ENHERTU REDUCED RISK OF DISEASE PROGRESSION BY 72% | View Document |
| 2021-09-09 | 6-K | IMFINZI IMPROVES SURVIVAL IN NSCLC IN POSEIDON | View Document |
| 2021-09-09 | 6-K | FIXED-DOSE COMBINATION OF ALBUTEROL AND BUDESONIDE (PT027) DEMONSTRATED SIGNIFIC | View Document |
| 2021-09-03 | 6-K | ULTOMIRIS APPROVED IN EU FOR CHILDREN WITH PNH | View Document |
| 2021-09-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2021-08-26 | 6-K | FORXIGA APPROVED IN JAPAN FOR CKD | View Document |
| 2021-08-26 | 6-K | ALXN1840 WILSON PHASE III MET PRIMARY ENDPOINT | View Document |
| 2021-08-20 | 6-K | UPDATE ON ULTOMIRIS PHASE III ALS TRIAL | View Document |
| 2021-08-20 | 6-K | AZD7442 PROPHYLAXIS TRIAL MET PRIMARY ENDPOINT | View Document |
| 2021-08-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-08-11 | 6-K | UPDATE ON US REVIEW OF ROXADUSTAT | View Document |
| 2021-08-09 | 6-K | FORXIGA APPROVED IN THE EU FOR CKD | View Document |
| 2021-08-09 | 6-K | ENHERTU HEAD-TO-HEAD TRIAL MEETS PRIMARY ENDPOINT | View Document |
| 2021-08-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2021-08-02 | 6-K | SAPHNELO APPROVED IN THE US FOR SLE | View Document |
| 2021-07-30 | 6-K/A | FORM 6-K/A | View Document |
| 2021-07-30 | 6-K | FORM 6-K | View Document |
| 2021-07-27 | SC 13G | SC 13G | View Document |
| 2021-07-26 | 6-K | ULTOMIRIS RECOMMENDED IN EU FOR CHILDREN WITH PNH | View Document |
| 2021-07-22 | 6-K | DIRECTORATE CHANGE | View Document |
| 2021-07-21 | 6-K | FORM 6-K | View Document |
| 2021-07-21 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-07-21 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2021-07-21 | 6-K | ACQUISITION OF ALEXION COMPLETED | View Document |
| 2021-07-19 | F-6EF | REGISTRATION OF AMERICAN DEPOSITAR RECEIPT SHARES | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
